GET HELP NOW

Wednesday, November 1, 2017

PARP inhibitor may be effective against some TNBC lacking BRCA mutations

http://ift.tt/eA8V8J The investigational PARP inhibitor talazoparib caused regression of patient-derived xenografts (PDXs) of triple-negative breast cancers (TNBC) that had BRCA mutations and also those that did not have BRCA mutations but had other alterations in DNA damage-repair pathways.

from http://ift.tt/2A4AyR7
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Children whose mothers use marijuana are more likely to try it at younger age

When mothers use marijuana during the first 12 years of their child's life, their cannabis-using children are more likely to start at an...